IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

It to Application of

Florence Bordon-Pallier, et al

Examiner:

To Be Assigned

Art Unit:

To Be Assigned

Application No.:

10/606/424

Filed:

 \boxtimes

June 26, 2003

Title: Novel Purine Derivatives, Preparation Method and Use as Medicines

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 13, 2003
Date of Deposit

Bonnie Stein Signature

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

╛	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		(1)	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
			to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.

For your information, US Patent 6,413,754 B1 is the English equivalent of WO 99/07836. Also enclosed, for the Examiner's convenience, is a copy of the International Search Report.

Respectfully submitted,

Irving Newman, Reg. No. 22,638 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-2785
Telefax (908) 231-2626
Aventis Docket No. 2541US CNT

inside this bo

Please type a plus sign inside this box.

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/PTC)		Compl te if Known			
				Application Number	10/606,424		
INFC	RMATION	DIS	CLOSURE	Filing Date	06-26-2003		
STA	TEMENT B	Y AF	PPLICANT	First Named Inventor	BORDON-PALLIER		
				Group Art Unit			
	(use as many she	ets as n	ecessary)	Examiner Name			
heet	1	of	2	Attorney Docket Number	2541 - US - CNT		

U.S. PATENT DOCUMENTS								
Cite No.1	U.S. Patent Number		Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	6,413,754 B1		FAY et al.	07-02-2002				

					·			
								
								
			· · · · · · · · · · · · · · · · · · ·					
	 			 	·			
								
				- '				
		Cite No. ¹ Number	No.1 Number (if known)	Cite No.1 Number Kind Code2 (if known) Name of Patentee or Applicant of Cited Document	Cite No.1 Number Kind Code2 (if known) Name of Patentee or Applicant of Cited Document MM-DD-YYYY			

				FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite No.1	Office	Foreign Patent Do Number4	cument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		wo	00/49018		IMBACH, et al	08-24-2000		T
		wo	97/16452		ZIMMERMANN, et al	05-09-1997		T
		wo	97/20842		MEIJER, et al	06-12-1997		\top
		wo	98/05335		LUM, et al	02-12-1998		\top
		WO	99/07705		GRAY, et al	02-18-1999		Т
		wo	99/07836		FAYE et al.	02-18-1999		$oxed{\bot}$
								士
				<u>.</u>				


Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449B/P	то		Complete if Kn wn		
		–		Application Number	10/606,424	
INFC	DRMATIO	N D	ISCLOSURE	Filing Date	06-26-2003	
STA	TEMENT	BY	APPLICANT	First Named Inventor	BORDON-PALLIER	
0.7.			/ (Group Art Unit		
	(use as many	sheet	s as necessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2541 - US - CNT	
•			•			

	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²						
		KOZIMA S et al., Formation of Organotin-Nitrogen Bonds III*. N-Trialkyltin-5-Subsituted Tetrazoles, J. Organometallic Chemistry, Vol. 33, 1971, pp 337-346							
	-								

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.